Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Tuesday, December 19th.
Several other analysts have also issued reports on the company. Zacks Investment Research lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. HC Wainwright initiated coverage on Sarepta Therapeutics in a research report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, October 27th. Barclays upped their target price on Sarepta Therapeutics from $46.00 to $49.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Sarepta Therapeutics in a research report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, five have given a hold rating and seventeen have assigned a buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $63.88.
Sarepta Therapeutics (NASDAQ:SRPT) traded down $0.15 on Tuesday, reaching $58.99. The company had a trading volume of 1,632,300 shares, compared to its average volume of 1,670,000. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $3,810.00, a price-to-earnings ratio of -28.92 and a beta of 1.37. Sarepta Therapeutics has a fifty-two week low of $26.26 and a fifty-two week high of $60.22.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. The firm had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the prior year, the company earned ($0.95) earnings per share. equities research analysts anticipate that Sarepta Therapeutics will post -3.07 earnings per share for the current year.
In related news, SVP Shamim Ruff sold 10,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. Insiders own 9.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Ameritas Investment Partners Inc. grew its position in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 2,474 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 2,493 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in Sarepta Therapeutics in the third quarter worth $204,000. Finally, Bayesian Capital Management LP purchased a new position in Sarepta Therapeutics in the second quarter worth $206,000. Hedge funds and other institutional investors own 82.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by BidaskClub” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/sarepta-therapeutics-srpt-downgraded-by-bidaskclub-to-hold.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.